FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088110674> ?p ?o ?g. }

• W3088110674 endingPage "S588" @default.
• W3088110674 startingPage "S588" @default.
• W3088110674 abstract "Upper tract urothelial carcinomas (UTUCs) are a rare subset of urothelial carcinomas arising from urothelial cells of the ureter up to the renal calyceal system. Radical nephroureterectomy (RNU) is the gold standard treatment for UTUC patients, but this surgery leads to high risk of relapse and death from cancer. The present meta-analysis aims to evaluate the role of platinum-based adjuvant chemotherapy (AC) for patients with locally advanced UTUCs (staged as either pT2–T4 N0–N3 M0 or pTany N1–3) after RNU. Eligible studies were identified using Pubmed/Medline, Cochrane library, Embase and meeting abstracts. Searches were last updated on March 30, 2020. Eligible studies reported survival and/or disease-free survival (DFS) outcomes expressed as hazard ratio (HR) and 95% confidence intervals (CIs) for patients treated with platinum-based AC compared to observation alone. Primary outcomes of interest were overall survival (OS), cancer-specific survival (CSS) and DFS. A total of 16 studies were eligible for analysis: 15 retrospective studies and 1 phase 3 randomized control trial (RCT). In total, data from 6275 patients were reported with median number of patients included in each cohort of 65 (range: 11–2491 patients) and a median follow-up of 37,5 months (range 17,8-53,9 months). In patients receiving platinum-based AC, rates of weighted median 5-years OS, CSS and PFS were 72,3%, 75% and 63,3%, respectively, and appeared to be superior compared to control. Platinum-based AC resulted in a 51% risk reduction disease relapse (pooled HR 0.49; 95% CI: 0.36–0.66), while the benefit in OS (pooled HR 0.80; 95% CI: 0.51–1.26) and CSS (pooled HR 0.87; 95% CI: 0.65–1.17) was not statistically significant compared to observation after RNU. Conversely, platinum-based AC showed a modest OS benefit with a pooled HR 0.75 (95% CI: 0.57–0.99) in a posthoc analysis combing multivariable HRs with estimated HRs from Kaplan-Meier curves. With available evidence from published data, we suggest that platinum-based AC is associated with improved DFS and a modest OS benefit after RNU in patients with locally advanced UTUCs. Further prospective randomized studies are needed to confirm our findings." @default.
• W3088110674 created "2020-10-01" @default.
• W3088110674 creator A5013505561 @default.
• W3088110674 creator A5016268842 @default.
• W3088110674 creator A5032386417 @default.
• W3088110674 creator A5042892518 @default.
• W3088110674 creator A5063795761 @default.
• W3088110674 date "2020-09-01" @default.
• W3088110674 modified "2023-10-18" @default.
• W3088110674 title "760P Platinum-based adjuvant chemotherapy in upper tract urothelial carcinomas (UTUCs): A change of paradigm? A meta-analysis of aggregate data" @default.
• W3088110674 doi "https://doi.org/10.1016/j.annonc.2020.08.832" @default.
• W3088110674 hasPublicationYear "2020" @default.
• W3088110674 type Work @default.
• W3088110674 sameAs 3088110674 @default.
• W3088110674 citedByCount "0" @default.
• W3088110674 crossrefType "journal-article" @default.
• W3088110674 hasAuthorship W3088110674A5013505561 @default.
• W3088110674 hasAuthorship W3088110674A5016268842 @default.
• W3088110674 hasAuthorship W3088110674A5032386417 @default.
• W3088110674 hasAuthorship W3088110674A5042892518 @default.
• W3088110674 hasAuthorship W3088110674A5063795761 @default.
• W3088110674 hasBestOaLocation W30881106741 @default.
• W3088110674 hasConcept C126322002 @default.
• W3088110674 hasConcept C126894567 @default.
• W3088110674 hasConcept C141071460 @default.
• W3088110674 hasConcept C143998085 @default.
• W3088110674 hasConcept C167135981 @default.
• W3088110674 hasConcept C207103383 @default.
• W3088110674 hasConcept C2776478404 @default.
• W3088110674 hasConcept C2776694085 @default.
• W3088110674 hasConcept C44249647 @default.
• W3088110674 hasConcept C71924100 @default.
• W3088110674 hasConcept C95190672 @default.
• W3088110674 hasConceptScore W3088110674C126322002 @default.
• W3088110674 hasConceptScore W3088110674C126894567 @default.
• W3088110674 hasConceptScore W3088110674C141071460 @default.
• W3088110674 hasConceptScore W3088110674C143998085 @default.
• W3088110674 hasConceptScore W3088110674C167135981 @default.
• W3088110674 hasConceptScore W3088110674C207103383 @default.
• W3088110674 hasConceptScore W3088110674C2776478404 @default.
• W3088110674 hasConceptScore W3088110674C2776694085 @default.
• W3088110674 hasConceptScore W3088110674C44249647 @default.
• W3088110674 hasConceptScore W3088110674C71924100 @default.
• W3088110674 hasConceptScore W3088110674C95190672 @default.
• W3088110674 hasLocation W30881106741 @default.
• W3088110674 hasOpenAccess W3088110674 @default.
• W3088110674 hasPrimaryLocation W30881106741 @default.
• W3088110674 hasRelatedWork W1900595920 @default.
• W3088110674 hasRelatedWork W2039727033 @default.
• W3088110674 hasRelatedWork W2430940777 @default.
• W3088110674 hasRelatedWork W2734975679 @default.
• W3088110674 hasRelatedWork W2768091966 @default.
• W3088110674 hasRelatedWork W2889691785 @default.
• W3088110674 hasRelatedWork W2893418727 @default.
• W3088110674 hasRelatedWork W3157589766 @default.
• W3088110674 hasRelatedWork W3185003217 @default.
• W3088110674 hasRelatedWork W4206071870 @default.
• W3088110674 hasVolume "31" @default.
• W3088110674 isParatext "false" @default.
• W3088110674 isRetracted "false" @default.
• W3088110674 magId "3088110674" @default.
• W3088110674 workType "article" @default.